NCT05546723
LMY-920 for Treatment of Relapsed or Refractory Myeloma No drug interventions treatment 1 recruiting NCT05121103
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma No drug interventions treatment 1 active_not_recruiting NCT05673083
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT05749133
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM No drug interventions treatment 1 / 2 recruiting NCT04813653
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells treatment 1 recruiting NCT05050305
Marizomib Central Nervous System (CNS) treatment 2 withdrawn NCT06012383
Alvocade® (Bortezomib) Safety and Effectiveness Study Not Available Not Available completed NCT05008536
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma treatment 0 unknown_status NCT02176213
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 2 completed NCT05493618
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. treatment 1 / 2 withdrawn NCT05836896
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT06115135
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma treatment 2 not_yet_recruiting NCT05909826
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM treatment 2 not_yet_recruiting NCT06485076
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma No drug interventions supportive_care Not Available recruiting NCT04861480
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 enrolling_by_invitation NCT06411301
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors treatment 1 not_yet_recruiting NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies treatment 0 recruiting NCT06225310
A Trial of Selinexor, Ruxolitinib and Methylprednisolone treatment 1 not_yet_recruiting NCT04688853
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients No drug interventions other 1 unknown_status NCT04811898
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment No drug interventions treatment 1 completed NCT04657861
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma No drug interventions treatment 0 recruiting NCT05739188
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM No drug interventions treatment 1 / 2 recruiting NCT04414475
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM treatment 2 recruiting NCT06242249
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 not_yet_recruiting NCT05495620
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma Not Available Not Available unknown_status NCT05555329
Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study treatment 4 not_yet_recruiting NCT05191472
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies treatment 2 terminated NCT06158412
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma treatment 2 recruiting NCT04287855
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT05747586
BCMA CAR-NK For Patients With RRMM treatment Not Available recruiting NCT04579523
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma treatment 1 not_yet_recruiting NCT06357975
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) treatment 2 active_not_recruiting NCT06357988
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) treatment 2 active_not_recruiting NCT06360575
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) treatment 2 active_not_recruiting NCT06421675
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma treatment 2 not_yet_recruiting NCT06433947
Study to Assess Safety and Tolerability of OPN-6602 in Subjects with Relapsed And/or Refractory Multiple Myeloma treatment 1 recruiting NCT06500884
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity treatment 2 active_not_recruiting NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT06622005
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 not_yet_recruiting NCT06627751
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease treatment 2 not_yet_recruiting NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers treatment 1 / 2 recruiting NCT04790474
Ixazomib-pomalidomide-dexamethasone As Second or Third-line Combination Treatment for Patients with Relapsed and Refractory Multiple Myeloma Previously Treated with Daratumumab, Lenalidomide and Bortezomib treatment 2 active_not_recruiting NCT05228470
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. treatment 1 / 2 active_not_recruiting NCT06303167
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) treatment 2 active_not_recruiting NCT06308822
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) treatment 2 active_not_recruiting NCT06518551
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM treatment 1 / 2 not_yet_recruiting NCT06588660
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 1 not_yet_recruiting NCT00047203
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT01233921
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer supportive_care Not Available completed NCT00028821
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT03618602
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients No drug interventions treatment 1 unknown_status NCT00619684
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant treatment 2 completed NCT04843579
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients treatment 2 terminated NCT04439279
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) treatment 2 active_not_recruiting NCT01534143
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant treatment 2 terminated NCT00002787
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation treatment 1 completed NCT00153933
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT00693433
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma treatment 1 completed NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer treatment 1 / 2 completed NCT00054353
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 / 2 completed NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy treatment 1 completed NCT00303797
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer treatment 1 completed NCT00054483
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction basic_science 1 completed NCT06385483
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) treatment 2 active_not_recruiting NCT01676961
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy supportive_care 2 terminated NCT05896228
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma treatment 2 recruiting NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma treatment 1 completed NCT05490771
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) treatment 2 active_not_recruiting NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma treatment 2 completed NCT03798678
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT04439188
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) treatment 2 active_not_recruiting NCT05053607
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab No drug interventions other Not Available recruiting NCT00079456
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT04398485
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 active_not_recruiting NCT00398515
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma treatment 1 completed NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT00514137
Sunitinib in Treating Patients With Relapsed Multiple Myeloma treatment 2 completed NCT06390852
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) treatment 2 active_not_recruiting NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT05577000
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT00995059
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 / 2 withdrawn NCT04883242
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 2 recruiting NCT00912899
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 terminated NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer treatment Not Available completed NCT00998049
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant treatment 2 completed NCT04119336
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma treatment 2 terminated NCT00306813
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT01384513
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies treatment 2 completed NCT05950113
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 withdrawn NCT02020941
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy treatment 2 terminated NCT01078441
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant treatment 2 terminated NCT04083534
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) No drug interventions treatment 1 / 2 active_not_recruiting NCT03601624
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans treatment 2 unknown_status NCT04302324
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab treatment 2 recruiting NCT00310024
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT06385496
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) treatment 2 active_not_recruiting NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT02103335
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma treatment 1 completed NCT00243035
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma treatment 1 / 2 terminated NCT05150522
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma No drug interventions treatment 1 / 2 unknown_status NCT03702725
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT06400225
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) treatment 2 active_not_recruiting NCT06390826
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) treatment 2 active_not_recruiting NCT00003166
Bryostatin and Vincristine in B-Cell Malignancies treatment 1 completed NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT03770260
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment treatment 1 completed NCT01074060
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma treatment 1 completed NCT03952091
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma treatment 3 completed NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Not Available Not Available completed NCT01118689
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia treatment 1 completed NCT04439292
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) treatment 2 active_not_recruiting NCT05020444
TriPRIL CAR T Cells in Multiple Myeloma treatment 1 recruiting NCT00114101
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant treatment 3 active_not_recruiting NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer treatment 2 completed NCT00060372
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer treatment 1 completed NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies treatment 2 completed NCT06203912
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 1 recruiting NCT03201250
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma treatment 1 / 2 terminated NCT05431608
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma No drug interventions treatment 1 recruiting NCT06348108
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma treatment 1 not_yet_recruiting NCT04004338
Carfilzomib in Combination for the Treatment of RR MM Not Available Not Available unknown_status NCT06400264
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) treatment 2 withdrawn NCT01083602
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma treatment 2 completed NCT01954784
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma treatment 1 terminated NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma treatment 1 / 2 completed NCT00003954
Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma treatment 1 / 2 completed NCT06400251
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) treatment 2 active_not_recruiting NCT00849251
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma treatment 1 / 2 terminated NCT04439253
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) treatment 2 active_not_recruiting NCT01775553
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib treatment 2 completed NCT04162353
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma No drug interventions treatment 1 unknown_status NCT01034553
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT03389347
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia No drug interventions other Not Available recruiting NCT02998047
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma treatment 1 terminated NCT05430945
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma No drug interventions treatment 0 recruiting NCT01049945
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma treatment 1 / 2 completed NCT00343798
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies treatment 1 completed NCT00124605
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma treatment 1 completed NCT01155583
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT00799461
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications No drug interventions supportive_care 3 completed NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00253578
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT03158688
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. treatment 3 completed NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders treatment Not Available completed NCT05981209
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies treatment 1 recruiting NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma treatment Not Available completed NCT06171685
Horizon Adaptive Platform Trial Evaluating Therapies in RRMM treatment 2 not_yet_recruiting NCT03520985
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma treatment 2 terminated NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT01564537
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma treatment 3 completed NCT03731832
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma screening 2 active_not_recruiting NCT01212952
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT04439175
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) treatment 2 active_not_recruiting NCT06138275
Elranatamab in R/R Multiple Myeloma treatment 2 recruiting NCT01076270
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment Not Available terminated NCT00118170
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function treatment 1 completed NCT04764942
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial treatment 1 / 2 recruiting NCT01096342
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT01653106
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients No drug interventions treatment Not Available completed NCT04439149
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) treatment 2 active_not_recruiting NCT04439136
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) treatment 2 active_not_recruiting NCT06304636
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT04439318
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) treatment 2 active_not_recruiting NCT04176718
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM treatment 2 recruiting NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT05742217
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases No drug interventions Not Available Not Available recruiting NCT05641324
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) treatment 1 terminated NCT02658396
GO-203-2C + Bortezomib For Relapsed Or Refractory MM treatment 1 withdrawn NCT00003196
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma treatment Not Available completed NCT01110135
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma treatment 2 completed NCT01301963
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide treatment 3 terminated NCT00182663
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant treatment 2 completed NCT04355039
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma treatment 1 withdrawn NCT03589222
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma treatment 2 unknown_status NCT03031730
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma treatment 1 terminated NCT04439357
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) treatment 2 active_not_recruiting NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) treatment 2 active_not_recruiting NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies supportive_care 2 completed NCT06352866
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM supportive_care 2 not_yet_recruiting NCT06390865
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) treatment 2 active_not_recruiting NCT02199665
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 recruiting NCT01812720
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant treatment 2 withdrawn NCT04802031
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma treatment 2 withdrawn NCT04439331
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) treatment 2 active_not_recruiting NCT04439227
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) treatment 2 active_not_recruiting NCT00112827
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma treatment 1 / 2 completed NCT04519476
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. treatment 1 recruiting NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer No drug interventions supportive_care Not Available completed NCT05170789
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma treatment 2 withdrawn NCT03266692
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma treatment 1 terminated NCT06232044
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 not_yet_recruiting NCT02101944
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT04439344
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) treatment 2 active_not_recruiting NCT00006244
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma treatment 2 completed NCT00536601
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors treatment Not Available completed NCT00719901
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT05922501
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma treatment 2 not_yet_recruiting NCT05847569
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma treatment 2 recruiting NCT04434469
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma No drug interventions treatment 1 completed NCT04439110
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) treatment 2 active_not_recruiting NCT01447914
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma treatment 2 completed NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 withdrawn NCT04670055
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma No drug interventions treatment 0 not_yet_recruiting NCT00112723
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma treatment 1 / 2 terminated NCT04439123
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) treatment 2 active_not_recruiting NCT05117008
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma treatment 2 terminated NCT03860038
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT06400238
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) treatment 2 active_not_recruiting NCT00217438
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma treatment 3 completed